A 35-year-old man as diagnosed with HIV infection in 1989. He was treated initially with
zidovudine monotherapy, then zidovudine, lamivudine and saquinavir in 1996, with the …

Background Fat abnormalities are common among HIV-infected persons, but few studies
have compared regional body fat distribution, including visceral fat, in HIV-infected and HIV …

Body composition alterations are common in HIV infection and include AIDS wasting and
lipodystrophy. Both are associated with metabolic alterations, including hypertriglyceridemia …

Approximately 50% of patients on highly active antiretroviral therapy (HAART) develop
lipodystrophy with central and visceral fat accumulation and/or facial and limb atrophy …

HIV‐associated lipodystrophy syndrome (HALS) is characterized by body fat redistribution
as a consequence of the antiretroviral therapy (ART) introduction, associated with an …

Objective To estimate the incidence of lipoatrophy and lipohypertrophy among HIV-infected
and HIV-uninfected women from the Women's Interagency HIV Study. Design Eight hundred …

Multiple complex strategies will need to be utilized in these patients to treat the different
features seen in lipodystrophy in order to reduce their long-term cardiovascular risk. Further …

AIDS: Lipodystrophy is defined as the defective metabolism of fat, and it is characterized by
distinct physical changes, such as an increased waist size or an accumulation of fatty tissue …

Lipodystrophy was first described in HIV-1-infected patients in 1998 [1–5]. The main clinical
feature is subcutaneous fat loss or lipoatrophy of the face, limbs, and buttocks [6, 7]. Patients …

Background HIV disease itself is associated with increased healthcare utilization and
healthcare expenditures. HIV-infected persons with lipodystrophy have been shown to have …